The Role of Ubiquitination in CRPC Transitioning to NEPC

Abstract

Castration-resistant prostate cancer patients rapidly become resistant to androgen receptor pathway inhibitors. About 20% of these patients develop a highly aggressive neuroendocrine prostate cancer. Currently no target therapy is available for neuroendocrine prostate cancer. Understanding the molecular mechanisms driving castration-resistant prostate cancer to become neuroendocrine prostate cancer would provide valuable insights into the development of target therapies. We recently found that an oncogenic enzyme, TRAF4, is important for castration-resistant prostate cancer development. It is also gene amplified in 25% of neuroendocrine prostate cancer patients. The goal of this proposed research is to understand the role of TRAF4 in neuroendocrine prostate cancer development. We will also test the effect of a potential TRAF4 enzyme inhibitor on controlling castration-resistant prostate cancer progression to neuroendocrine prostate cancer.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Aug 01, 2022
Accession Number
AD1177760

Entities

People

  • Ping Yi

Organizations

  • Baylor College of Medicine

Tags

DTIC Thesaurus Topics

  • Androgen Receptors
  • Androgens
  • Antibodies
  • Biomedical Research
  • Cancer
  • Castration
  • Cell Line
  • Cells
  • Department Of Defense
  • Enzyme Inhibitors
  • Gene Expression
  • Inhibition
  • Inhibitors
  • Maryland
  • Molecules
  • Neoplasms
  • Prostate
  • Prostate Cancer
  • Proteins
  • Small Molecules
  • Standards

Readers

  • Molecular Biology and Genetics
  • Prostate Cancer Biology.